Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [1] Drug therapies for metastatic castration-resistant prostate cancer
    El-Bahesh, Ehab
    Finianos, Antoine
    Alfaraj, Abeer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2015, 11 (17) : 2395 - 2403
  • [2] Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis
    Liang, Xiao
    Hu, Kebang
    Li, Dawei
    Wang, Yanbo
    Liu, Min
    Wang, Xiaoxue
    Zhu, Wanying
    Wang, Xinyu
    Yang, Zixuan
    Lu, Ji
    DNA AND CELL BIOLOGY, 2020, 39 (05) : 836 - 847
  • [3] Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors
    Pavlov, A. Yu.
    Dzidzaria, A. G.
    Gafanov, R. A.
    Samusevich, V. A.
    Mirzoev, E. E.
    Kortyshkova, A. O.
    Aivazov, M. T.
    Mirzoev, F. E.
    ONKOUROLOGIYA, 2024, 20 (01): : 153 - 163
  • [4] Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
    Tsai, Alexander K.
    Kagalwalla, Sana
    Langer, Jenna
    Le-Kumar, Thuy
    Le-Kumar, Vikas
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 51 - 62
  • [5] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [6] Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
    El-Amm, Joelle
    Patel, Nihar
    Freeman, Ashley
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 235 - 245
  • [7] Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
    Perez-Navarro, Enrique
    Conteduca, Vincenza
    Funes, Juan M.
    Dominguez, Jose I.
    Martin-Serrano, Miguel
    Cremaschi, Paolo
    Piedad Fernandez-Perez, Maria
    Gordoa, Teresa Alonso
    Font, Albert
    Vazquez-Estevez, Sergio
    Gonzalez-del-Alba, Aranzazu
    Wetterskog, Daniel
    Mellado, Begona
    Fernandez-Calvo, Ovidio
    Jose Mendez-Vidal, Maria
    Angel Climent, Miguel
    Duran, Ignacio
    Gallardo, Enrique
    Rodriguez Sanchez, Angel
    Santander, Carmen
    Isabel Saez, Maria
    Puente, Javier
    Tudela, Julian
    Marinas, Cecilia
    Jose Lopez-Andreo, Maria
    Castellano, Daniel
    Attard, Gerhardt
    Grande, Enrique
    Rosino, Antonio
    Botia, Juan A.
    Palma-Mendez, Jose
    De Giorgi, Ugo
    Gonzalez-Billalabeitia, Enrique
    CANCERS, 2024, 16 (14)
  • [8] Advances in systemic therapies for metastatic castration-resistant prostate cancer
    Pant, Manish K.
    Abughaban, Ahmed
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (14) : 2213 - 2226
  • [9] Treatment strategies in low-volume metastatic castration-resistant prostate cancer
    Wei, Xiao X.
    Ko, Eric C.
    Ryan, Charles J.
    CURRENT OPINION IN UROLOGY, 2017, 27 (06) : 596 - 603
  • [10] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229